Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Portuguese in vitro antibiotic susceptibilities favor current nontuberculous mycobacteria treatment guidelines
Pulmonology, Volume 25, No. 3, Year 2019
Notification
URL copied to clipboard!
Description
Setting: Nontuberculous mycobacteria (NTM) are increasingly recognized as causative agents of opportunistic infections in humans for which effective treatment is challenging. There is, however, very little information on the prevalence of NTM drug resistance in Portugal. Objective and Design: Our aim was to analyze the drug susceptibility testing (DST) performed in NTM at the Portuguese National Health Institute Dr. Ricardo Jorge from February 2003 to February 2016. A total of 262 DST were included in the analysis. Results: Most (94%) M. avium intracellulare complex isolates showed in vitro susceptibility to clarithromycin. All M. kansasii isolates were susceptible to rifampicin and ethambutol and 97.1% were susceptible to isoniazid. The majority of rapidly-growing mycobacteria (RGM) demonstrated in vitro susceptibility to amikacin, clarithromycin and cefoxitin. However, in RGM there was a marked increase on the relative risk of having sulfamethoxazole resistance in isolates resistant to ciprofloxacin compared to susceptible isolates. Conclusion: Tested NTM in Portugal revealed in vitro susceptibility to most of the antimicrobials currently recommended for treatment. However, our results also suggest that sulfamethoxazole should be avoided in treatment of RGM resistant to ciprofloxacin (or vice versa). Further trials that correlate the in vitro DST results with the clinical outcome are needed in order to reach conclusions on efficient antimicrobial therapy. © 2018 Sociedade Portuguesa de Pneumologia
Authors & Co-Authors
Silva, Anabela Santos
Portugal, Marateca
Instituto Nacional de Saúde Doutor Ricardo Jorge
MacEdo, Rita
Portugal, Marateca
Instituto Nacional de Saúde Doutor Ricardo Jorge
Duarte, R. A.B.
Portugal, Vila Nova de Gaia
Centro Hospitalar de Vila Nova de Gaia
Portugal, Porto
Universidade do Porto
Statistics
Citations: 2
Authors: 3
Affiliations: 5
Identifiers
Doi:
10.1016/j.pulmoe.2018.09.001
ISSN:
25310429
Study Design
Cross Sectional Study